Swiss Pharmacueticals Shortages: The Temesta Case

The Pharmaceutical Paradox in Switzerland: Shortages and Solutions

The enigma of the lack of essential medicines in Switzerland is a subject. Sixty percent of therapeutic specialties needed in Switzerland are unavailable.Out of these, more than 100 are critically needed to treat various ailments ranging from anxiety to life-threatening conditions. This puzzle is exemplified by the abrupt disappearance of Temesta, an anxiolytic commonly prescribed for sleep disorders and anxiety, from Swiss pharmacy shelves in the spring of 2023.

The Vanishing Act of Temesta

The shortfall of Temesta, manufactured by Pfizer, caused chaos. Within a few weeks, the drug became scarce. The blame lies with the producer, Pfizer. Pfizer drastically reduced its supply to Switzerland citing unconfirmed problems with its production chain.

The Ripple Effect of Drug Shortages

When a critical drug like Temesta disappears from the shelves, the burden falls on doctors and pharmacists to manage the resulting health crisis. In practical terms, this means presenting medicines like Seresta to those having anxiety. The change has resulted in mixed patient reactions. Some elderly patients tolerated the alternative well, whilst a few suffered from excessive daytime sleepiness. In extreme cases, some endured short-term hallucinations.

Finding Solutions Across Borders

When supply becomes an issue, Switzerland allows for the importation of medications. This has meant that many locals have resorted to buying medications at Italian border pharmacies. The equivalent to Temesta in Italy, Tavor, has not had shortages. The demand has been so high over the past year that over 10 pharmacists daily has been required to assist in the distribution of Tavor and its 11 generics to Swiss nationals.

Navigating Production Shortfalls with Local Solutions

Facing the shortage, manual labor manufacturing of Lorazepam has been the lifeline.A laboratory in Switzerland, Laboratorio Golaz of Losanna, pumped out 15,000 packs in a few months, aiding many pharmacies. Pricing was a setback, sending a single box selling for about 60 Swiss Francs. The price tag was four times more than the original drug.

The Economics of Health

Affordable drugs in Switzerland such as pain medications and antibiotics have downturned due to the market pressure of low prices. Peter Burkard, president of the Ticino Pharmacists’ Association, has the market volume in Switzerland being minuscule and profit margins low. The pressing need for profitability has steered Swiss pharma to innovative and expensive medicines.

The introduction of policies that guarantee medicine availability seems like the solution. Incentives for production and revenue sustainability need to be addressed. New ruling has pressured the government to loosen import standards and establish a firm foundation for drug pricing.

Innovative Solutions from Local Enterprises

Registering progressive ventures like Zedaxin and Sedazin, Bellinzona’s Lagap has introduced Godwin Sedazin and Zedaxin generics. The cost for each of these drugs is $11:65 but has only yielded $2:23 for Lagap covering every transaction. A worryingly lean margin that can’t sustain Lagap depends on the current economic shifts.”

Why Some Drugs Disappear

For veteran pharmacists like Giovan Maria Zanini, presiding over Ticino’s pharmaceuticals, the medicines that should be available for over 20 years are missing. Zanini traced the timelines stating that the price plunge was camouflaged with fiscal rationales in the years 2000. The series of discounts started off with the enforcement of the 2000 regulation that aligned Switzerland medicinal market with Europe. The review sanctioned at every three years has caused a steady decline.

The depreciation rate of the Euro sped up the process. About 20 years back, €1 was worth SFr 1:60, now a little less than a franc. The anti-parallel market shift arises from the regulatory principles forcing the price cuts over the years.

The situation in Bioggio, Ticino, had minimal improvements. Content supply for Swiss domestic population is still as elusive. Continually facing low volumes and low profits means pharmaceuticals are turning their attention towards research in novel medicines.

FAQ Section

What happens when a drug goes missing in Switzerland?

The absence of a medication causes confusion for doctors, pharmacists, and patients as alternative options are often limited or costly. Many patients, for example, find it hard to switch medication causing unpleasant side effects. The system is running on little to nothing. The field functionally relies on imports and Dominican are limited in providing provisional coverage. As the question looms, what next? What else can be done.

Are there laws in Switzerland that allow for import of foreign drugs?

Yes, Switzerland has regulations allowing the import of medicines when domestic supplies are depleted and patients require the drugs. This was the case with Tusor following the disappearance of Temesta.

How much more would local manufacture of medications cost?

The costs are relatively higher, the example drawn is the Sedazin. The generic is worth Sfr 11:65 to retailers. But, manufactures compensate handsomely getting Sfr 2:23 with the margin being unsustainable.

What is driving up the cost of drug production in Switzerland?

Economic deterioration and regulation are the top drivers creating a depressing feeling amongst large local manufacturers, the continued downsized volume in local factories with unforeseen costs creates a vexing situation.

How many key pharmaceuticals are scarce in Switzerland?

Key pharmaceuticals currently not available for the Swiss population are conservatively estimated at 600 with 100 of the being critically needed

What Action Needs to Turn This Around?

The writers and economists are calling for a more local firm production and stringent controls on imports for provision approaches required to cushion the developing dwindling market and widen margins. Still, the crisis according to Zanini will be prolonged.

However, experts don’t forget to recommend the latest approach with cases in hand could propel growth!

Expert tips

“Managing a scarcity by on brand equalties is best. However, pushing for an increase in margins and supply by local prowess in manufacturing.”—Madison.

What’s your take on this provisions crisis? Do let us know in the comments. Subscribe to this platform to keep stay updated, it’s simple.
Pro tip. When taking or prescribing new medications, stay flexible. Need a clear inception, approach as consistently. Switching unlikely to go smoothly!